Home>Topics>Companies>Novartis

Novartis NVS

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. New Morningstar Analyst Report for Roche Holding AG

      Stock Reports

      Mon, 28 Jul 2014

      pooled voting rights--including board members Andre Hoffmann and Andreas Oeri--owns 45% of voting shares, and Novartis owns 33% of voting shares. Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical

    2. Glaxo to hold onto consumer healthcare division

      Headlines

      Mon, 28 Jul 2014

      has no plans to spin off its consumer healthcare division according to Bloomberg . It is proceeding with a JV with Novartis ( NVS -0.8% ) to create a consumer health company with ~6.5B pounds ($11B) in annual revenue. The transaction

    3. Why Pfizer Will Trade At $40 On Improved Drug Pipeline

      Headlines

      Mon, 28 Jul 2014

      still cheap. Pfizer is trading at a P/E that is almost 30 points below Merck (NYSE: MRK ), 13 points below Novartis (NYSE: NVS ) and 15 point below Sanofi (NYSE: SNY ). This makes Pfizer a candidate for the best bargain in Big Pharma

    4. Novartis says Alcon glaucoma treatment approved in EU

      Headlines

      Mon, 28 Jul 2014

      ZURICH, July 28 (Reuters) - Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.

    5. Prozac Nation, Street Version

      Headlines

      Fri, 25 Jul 2014

      physician education sessions, expanded 49%. During the conference call, management mentioned that contracts with Novartis NVS and King Pharmaceuticals KG have started contributing to this segment. Revenues from the prepackaged medications segment

    6. FDA accepts BLA for biosimilar of Amgen's Neupogen

      Headlines

      Thu, 24 Jul 2014

      The FDA accepts the Biologics License Application (BLA) for filgrastim filed by Novartis ' ( NVS +0.3% ) Sandoz. The reference product is Amgen's ( AMGN +0.1% ) Neupogen . Sandoz markets the product under the brand

    7. New Morningstar Analyst Report for GlaxoSmithKline PLC

      Stock Reports

      Thu, 24 Jul 2014

      2014 restructuring of divisions with Novartis should bode well for Glaxo. In the ..... completion of the restructuring with Novartis (2015), we forecast average annual ..... completion of the restructuring with Novartis (2015), we forecast average annual

    8. XLV Health Care Select Sector SPDR® ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Thu, 24 Jul 2014

      criteria eliminate foreign health-care companies, the index excludes international health-care behemoths such as Novartis NVS , GlaxoSmithKline GSK, Roche, and Sanofi SNY. That said, we'd note that most of the firms included here are large

    9. IYH iShares US Healthcare ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Thu, 24 Jul 2014

      fund does not own companies that are domiciled overseas. As a result, international health-care behemoths such as Novartis NVS , GlaxoSmithKline GSK, Roche, and Sanofi SNY are nowhere to be found. That said, many of the firms in this ETF have

    10. VHT Vanguard Health Care ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Thu, 24 Jul 2014

      owns only companies domiciled in the United States, which means that it doesn't invest in foreign behemoths such as Novartis NVS , Roche, and Sanofi SNY. That said, many of the companies in VHT operate businesses spanning the globe, which ensures

    « Prev12345Next »
    Content Partners